Pieris Pharmaceuticals, Inc. (PIRS)
Largest Insider Buys in Sector
PIRS Stock Price History Chart
PIRS Stock Performance
About Pieris Pharmaceuticals, Inc.
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in human blood plasma and other bodily fluids. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other …
Insider Activity of Pieris Pharmaceuticals, Inc.
Over the last 12 months, insiders at Pieris Pharmaceuticals, Inc. have bought $92,327 and sold $0 worth of Pieris Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Pieris Pharmaceuticals, Inc. have bought $37,029 and sold $2.9M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ADAR1 Capital Management, LLC (10 percent owner) — $92,326. GERAGHTY JAMES A (director) — $3.
The last purchase of 3,000 shares for transaction amount of $47,647 was made by ADAR1 Capital Management, LLC (10 percent owner) on 2024‑08‑12.
List of Insider Buy and Sell Transactions, Pieris Pharmaceuticals, Inc.
| 2024-08-12 | 10 percent owner | 3,000 0.2278% | $15.88 | $47,647 | +5.88% | |||
| 2024-08-09 | 10 percent owner | 3,000 0.2232% | $14.89 | $44,679 | +10.95% | |||
| 2024-08-07 | director | 1 – | $1.00 | $1 | +2.07% | |||
| 2023-05-25 | director | 10,000 0.0139% | $0.85 | $8,500 | -76.04% | |||
| 2022-05-13 | Chief Medical Officer | 6,000 0.0081% | $1.71 | $10,260 | -19.01% | |||
| 2021-08-30 | Sale | Chief Development Officer | 38,400 0.0581% | $5.11 | $196,380 | -36.47% | ||
| 2020-07-21 | Sale | 10 percent owner | 1.9M 3.4847% | $2.95 | $5.61M | -6.93% | ||
| 2019-09-06 | Sale | 10 percent owner | 50,000 0.1024% | $4.50 | $224,970 | -27.75% | ||
| 2018-09-14 | director | 5,000 0.0095% | $5.11 | $25,525 | -27.05% | |||
| 2018-05-15 | director | 10,000 0.0185% | $5.75 | $57,500 | -33.22% | |||
| 2018-04-30 | Sale | 10 percent owner | 1M 1.8466% | $6.35 | $6.35M | -31.24% | ||
| 2018-02-13 | Sale | 10 percent owner | 15,794 0.03% | $8.98 | $141,830 | -43.70% | ||
| 2018-01-03 | Sale | 10 percent owner | 3.42M 7.0529% | $7.35 | $25.13M | -21.91% | ||
| 2017-12-18 | Sale | 10 percent owner | 295,270 0.5963% | $5.70 | $1.68M | +0.35% | ||
| 2017-08-17 | See Remarks | 40,000 0.0952% | $4.89 | $195,600 | +28.08% | |||
| 2017-08-17 | director | 10,000 0.0235% | $4.82 | $48,200 | +28.08% | |||
| 2017-08-16 | See Remarks | 90,000 0.2049% | $4.79 | $431,100 | +25.11% | |||
| 2016-06-14 | SVP, Chief Development Officer | 7,915 0.0202% | $1.71 | $13,535 | +5.18% | |||
| 2016-06-13 | President and CEO | 12,000 0.0292% | $1.68 | $20,160 | +1.78% | |||
| 2016-06-13 | SVP, Chief Financial Officer | 5,000 0.012% | $1.66 | $8,300 | +1.78% |
Insider Historical Profitability
| ADAR1 Capital Management, LLC | 10 percent owner | 129574 9.8144% | $15.93 | 2 | 0 | |
| GERAGHTY JAMES A | director | 1 0.0001% | $15.93 | 3 | 0 | <0.0001% |
| Khuong Chau Quang | 7194222 544.9177% | $15.93 | 1 | 0 | <0.0001% | |
| Reine Allan | See Remarks | 65000 4.9233% | $15.93 | 2 | 0 | +26.59% |
| ORBIMED ADVISORS LLC | 10 percent owner | 38870 2.9442% | $15.93 | 1 | 4 | <0.0001% |
Institutional Investor Ownership
| Bvf Inc Il | $3.78B | 1561.07 | 20.61M | 0% | +$0 | 27.64 | |
| Lynx1 Capital Management Lp | $1.61B | 664.97 | 8.78M | -10.2% | -$182.59M | 84.78 | |
| Renaissance Technologies | $262,000.00 | 108.28 | 1.43M | +34.23% | +$66,816.61 | <0.0001 | |
| BlackRock | $190.1M | 78.6 | 1.04M | <0.01% | -$19,785.66 | <0.01 | |
| Citadel Advisors LLC | $177.2M | 73.26 | 967,235 | -18.71% | -$40.79M | 0.1 |